Log In
Print
BCIQ
Print
Print this Print this
 

CVT-301

  Manage Alerts
Collapse Summary General Information
Company Acorda Therapeutics Inc.
DescriptionInhaled formulation of levodopa delivered via Acorda's Arcus inhalation technology
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat "off" episodes in patients with fluctuating Parkinson's disease (PD); Treat motor fluctuations associated with Parkinson's disease (PD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$525.0M

$525.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today